FDA Tobacco Regulation

The FDA gained authority to regulate tobacco products under the Family Smoking Prevention and Tobacco Control Act (2009) — codified at 21 U.S.C. §§ 387–387t — ending more than a century in which cigarettes were sold with almost no federal oversight of their composition, marketing, or distribution. The law gave FDA power to restrict tobacco advertising and sales to minors, require disclosure of ingredients and additives, mandate health warnings, and regulate the design and components of tobacco products — but notably cannot ban nicotine outright and cannot eliminate the sale of existing tobacco products. Since 2016, FDA authority has extended to e-cigarettes, cigars, hookah, and pipe tobacco through the "Deeming Rule," requiring manufacturers to submit applications for products to remain on the market. The youth vaping epidemic — which saw e-cigarette use among high school students exceed 27% at its 2019 peak — forced FDA to accelerate its market authorization process and remove millions of unauthorized flavored vape products. As of 2026, manufacturers who submitted Premarket Tobacco Product Applications (PMTAs) by the required deadlines are under active FDA review; those who missed deadlines or received marketing denial orders face FDA enforcement. The tobacco regulatory landscape is in active flux: nicotine pouch products like Zyn, the menthol cigarette ban proposal, and reduced-nicotine cigarette rules are among the highest-stakes pending FDA actions.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 387a — FDA authority over tobacco products (authority to regulate manufacture, distribution, and marketing of tobacco products; protect public health; does NOT ban tobacco or nicotine entirely)
• 21 U.S.C. § 387c — Misbranded tobacco products (labeling requirements; health warnings; ingredient disclosure)
• 21 U.S.C. § 387d — Reporting and registration (manufacturers must register with FDA and list products; ingredient reporting; health data submissions)
• 21 U.S.C. § 387e — Annual registration; listing of tobacco products
• 21 U.S.C. § 387f — General provisions respecting the regulation of tobacco products (tobacco product standards — FDA may set standards for nicotine levels, ingredients, components, and design features; may NOT ban tobacco or reduce nicotine to zero)
• 21 U.S.C. § 387j — Premarket review (PMTA — new tobacco products must demonstrate they are "appropriate for the protection of the public health"; considers population-level effects including likelihood of use by non-users and youth)
• 21 U.S.C. § 387k — Modified risk tobacco products (MRTP — claims that a product reduces harm or risk of disease require FDA authorization based on scientific evidence)
• 21 U.S.C. § 387p — Preservation of state and local authority (states and localities may adopt additional restrictions on tobacco sales, distribution, and marketing — federal law is a floor, not a ceiling)

How It Works

The Family Smoking Prevention and Tobacco Control Act gave the FDA authority to regulate tobacco products for the first time — one of the most significant public health regulatory expansions in decades. FDA cannot ban tobacco, but it can regulate virtually everything about how tobacco products are made, marketed, and sold.

Under the Family Smoking Prevention and Tobacco Control Act, the FDA has authority over the manufacture, distribution, marketing, and sale of all tobacco products — one of the most significant public health regulatory expansions in recent decades. FDA cannot ban tobacco outright, but it controls product composition (including the 2009 ban on flavored cigarettes, excluding menthol), health warning requirements, advertising and promotion restrictions, minimum age requirements, and retail compliance inspections. A 2016 "deeming rule" extended FDA authority to e-cigarettes, cigars, hookah, and pipe tobacco — products previously unregulated at the federal level. Since the deeming rule, all e-cigarettes and other "new" tobacco products must obtain FDA marketing authorization through the Premarket Tobacco Product Application (PMTA) process, demonstrating the product is "appropriate for the protection of the public health" — a standard that weighs the risk-reduction benefit to adult smokers seeking alternatives against the risk of youth initiation. FDA has denied marketing authorization for millions of unauthorized e-cigarette products, particularly flavored products that appeal to youth, though enforcement against unauthorized market entrants remains an ongoing challenge.

The most consequential pending regulatory action is FDA's proposed ban on menthol in cigarettes and characterizing flavors in cigars. Menthol cigarettes represent approximately 37% of U.S. cigarette sales and are used by roughly 85% of Black smokers — making the menthol question both a major public health issue and a contentious equity debate about disproportionate policing consequences. The proposed ban has been in regulatory limbo for years and has not been finalized. Youth tobacco prevention is a separate statutory mandate: FDA has restricted advertising near schools, prohibited free samples, and conducted major retail enforcement campaigns against sales to minors. The rapid rise of youth e-cigarette use — the "vaping epidemic" peaking around 2019 — triggered emergency agency actions and accelerated the PMTA enforcement timeline. In December 2019, an appropriations act raised the federal minimum tobacco purchase age from 18 to 21 nationwide ("Tobacco 21"), with all states now subject to the federal floor regardless of state law.

How It Affects You

If you use tobacco or nicotine products: FDA regulations shape what products are legally on the market, what ingredients they contain, what health warnings you see, and how they can be sold to you. All cigarettes must display Surgeon General's health warnings; graphic warnings have been proposed for years but remain blocked by litigation. Any e-cigarette or vaping product you purchase is supposed to have FDA premarket tobacco product application (PMTA) authorization — but millions of unauthorized products are on the market because FDA enforcement hasn't kept pace with the influx. Tobacco cessation is covered as a preventive service under essential health benefits in ACA-compliant plans, and Medicaid expansion states cover cessation drugs and counseling. If you're trying to quit, FDA has authorized certain nicotine replacement therapies (patches, gum, lozenges) and prescription medications (varenicline/Chantix, bupropion) as smoking cessation aids — these are regulated as drugs, not tobacco products, and are covered by many insurance plans and Medicaid in states that comply with the Helping Tobacco Users Quit Act requirements. If you're interested in harm reduction, only modified-risk tobacco products (MRTPs) with explicit FDA authorization can legally claim reduced risk — the "snus" products authorized by FDA are the primary examples; most vaping claims of reduced harm lack FDA MRTP authorization.

If you're a parent or if you're under 21: Federal law prohibits the sale of any tobacco or e-cigarette product to anyone under 21 nationwide (the Tobacco 21 provision, enacted December 2019). This covers cigarettes, vapes, cigars, smokeless tobacco, hookah, and nicotine pouches. Retailers must verify age and face FDA enforcement actions — warning letters, civil money penalties, and no-tobacco-sale orders — for selling to minors. FDA has deployed compliance inspection programs where underage inspectors attempt to purchase tobacco products at retail locations, and retailers who fail are cited. For parents concerned about youth vaping: FDA's crackdown on flavored e-cigarette products has focused particularly on fruit and candy flavors that drove the youth vaping epidemic (peak: over 27% of high school students in 2019, down to single digits by 2024). However, disposable vapes and nicotine pouches continue to attract youth despite PMTA denial orders against many products. School districts can adopt tobacco-free campus policies that go beyond federal requirements.

If you're a tobacco retailer — convenience store, vape shop, smoke shop, or gas station: FDA conducts compliance inspections at retail locations — your store may be visited by an FDA contractor or state agent working under FDA's contract compliance program. Violations that can trigger penalties: selling to anyone under 21 (no exceptions for perceived older appearance without ID verification); selling any product not on FDA's authorized product list (this is trickier than it sounds — the market is full of unauthorized vaping products); failing to display required health warning signs; and accepting payments for self-service display of unauthorized products. Penalty structure: first violation — warning letter; subsequent violations — civil money penalties; repeat violations — no-tobacco-sale (NTS) orders that prohibit any tobacco product sales for a specified period. Register your tobacco product lines at FDA and verify authorization status before stocking new products — particularly new e-cigarette brands and disposables that enter the market frequently.

If you're a public health advocate, state health official, or local policymaker: The federal Tobacco Control Act is explicitly a floor, not a ceiling under 21 U.S.C. § 387p — states and localities can adopt restrictions that go beyond federal minimum requirements. Dozens of states and hundreds of municipalities have exercised this authority: California (and many other states) has banned all flavored tobacco products including menthol; Massachusetts was the first state to ban flavored tobacco statewide; state tobacco excise taxes range from $0.17/pack (Missouri) to $5.35/pack (Connecticut/New York), with higher taxes consistently associated with reduced smoking rates. The FDA's long-delayed proposed menthol cigarette ban — unfinalized as of 2026 — would be the most consequential tobacco regulation in history, but state and local action has moved faster. Local retail density ordinances limiting the number of tobacco retailers per neighborhood have shown promise in reducing youth access. If the federal menthol proposal stalls, state-level action is the primary avenue for this intervention.

State Variations

Federal tobacco regulation is a floor — states and localities can impose additional restrictions:

• Many states and cities have banned flavored tobacco products (including menthol)
• State tobacco excise taxes range from ~$0.17/pack (Missouri) to ~$5.35/pack (Connecticut/New York)
• Some localities have restricted the number and location of tobacco retail licenses

• State clean indoor air laws vary from comprehensive smoking bans to limited restrictions
• Some states regulate e-cigarettes more strictly than federal law

Implementing Regulations

• 21 CFR Part 1100 — Tobacco Product Regulation Scope (General): FDA's foundational regulations establishing which products are subject to tobacco product regulation under Chapter IX of the FDCA, as amended by the Family Smoking Prevention and Tobacco Control Act (2009). Part 1100 includes the "deeming rule" expanding FDA authority beyond the four original categories (cigarettes, cigarette tobacco, roll-your-own, smokeless) and the recordkeeping requirements for manufacturers of pre-existing products. Key provisions:

  • § 1100.1 — Scope of FDA authority (deeming rule): in addition to FDA's original authority over cigarettes, cigarette tobacco, roll-your-own tobacco, smokeless tobacco, and nicotine products not derived from tobacco, FDA deems all other products meeting the statutory definition of "tobacco product" to be subject to Chapter IX regulation; the deeming rule (finalized in May 2016, effective August 2016) brought under FDA jurisdiction: cigars, cigarillos, pipe tobacco, e-cigarettes, vapes, and hookah (waterpipe) tobacco; the effect is that manufacturers of these products must: comply with adulteration and misbranding provisions, submit premarket applications for new products, register with FDA, submit ingredient listings, and comply with all Chapter IX requirements
  • § 1100.2 — Requirements applicable to all tobacco products: all tobacco products subject to FDA authority (whether original or deemed) are subject to the same underlying statutory provisions — adulteration prohibitions, misbranding prohibitions, registration, product listing, premarket review, and manufacturing standards; the specific implementing regulations for each product category may differ in operational detail but all products are subject to the same legal framework
  • § 1100.3 — Definitions: "tobacco product" means any product made or derived from tobacco intended for human consumption; "accessory" means a product intended for use with tobacco products that does not itself contain tobacco (e.g., vape batteries, hookah pipes without tobacco) — accessories are NOT themselves regulated as tobacco products, though the tobacco products used with them are; this distinction matters for retailers who sell accessories independently
  • § 1100.5 — Exclusion from tobacco regulation: if a product made from tobacco is intended for use as a drug, device, or combination product (i.e., for therapeutic purposes), it is regulated under the drug/device provisions of the FDCA rather than Chapter IX tobacco provisions; tobacco-derived pharmaceutical nicotine (e.g., nicotine replacement therapies like patches and gum approved as drug products) is not subject to tobacco product regulation; the boundary between tobacco products and drug products was established in FDA v. Brown & Williamson (2000) and refined by the Tobacco Control Act
  • §§ 1100.200–1100.204 — Pre-existing tobacco products recordkeeping: manufacturers of "Pre-Existing Tobacco Products" — products commercially marketed in the United States before February 15, 2007 — must maintain records demonstrating the product's pre-2007 marketing date; this documentation matters because products marketed before the "predicate date" may use the Substantial Equivalence (SE) pathway for premarket authorization rather than the more stringent Premarket Tobacco Product Application (PMTA) pathway; manufacturers must retain records showing commercial marketing (sales, distribution) existed prior to that date for each specific product formulation

  The 2016 deeming rule fundamentally changed the tobacco product market by subjecting e-cigarettes and vapes to the same premarket review requirements as traditional tobacco products. Manufacturers of deemed products that were on the market after August 8, 2016 (the effective date) were required to submit PMTAs by September 2020; manufacturers that failed to submit by that deadline faced FDA enforcement. The FDA's subsequent review of PMTA applications — authorizing a small number of tobacco-flavored e-cigarettes while denying most flavored products — reshaped the e-cigarette market and generated extensive litigation. Recent rulemakings: 81 FR 28974 (May 2016) — deeming rule final rule extending FDA authority to cigars, e-cigarettes, and other products.

• 21 CFR Part 1107 — Premarket tobacco product applications: FDA's authority to issue orders finding that new tobacco products are not appropriate for the protection of the public health; provides the statutory basis for marketing denial orders (MDOs) and the framework for FDA to issue marketing granted orders (MGOs) for products that meet the "appropriate for the protection of the public health" standard

• 21 CFR Part 1114 — Premarket Tobacco Product Applications (PMTA Procedures): the procedural regulations governing how manufacturers submit, and how FDA reviews, premarket tobacco product applications under section 910 of the FDCA. Part 1114 was finalized in 2021 (86 FR 55300) as the operational rulebook for a process that FDA had been conducting under guidance since 2016 — the COVID-era surge in PMTA submissions (over 6.5 million applications submitted by the September 2020 deadline, overwhelmingly for e-cigarettes and vapor products) made formal procedural rules essential for managing the review process. Key provisions:

  • § 1114.5 — Application submission: a PMTA must be submitted to FDA's Center for Tobacco Products (CTP) using the required electronic format; new tobacco products may not be introduced into commerce until FDA issues a marketing granted order; the submission must include all data and information required under § 1114.7; incomplete applications will not be accepted
  • § 1114.7 — Required content and format: the PMTA must contain sufficient information for FDA to determine whether grounds for a marketing denial order exist; specifically, the application must include: (1) a full description of the product and its components; (2) a description of the methods and controls used in the manufacturing of the product; (3) the composition, ingredients, and additives; (4) data on health risks including toxicological, pharmacological, behavioral, and epidemiological studies; (5) information about use patterns and likely user populations; (6) a statement of the quantitative composition; the "appropriate for the protection of the public health" standard requires FDA to weigh population-level effects — a product that helps some adults quit smoking but initiates youth into tobacco use may not meet the standard despite individual benefit
  • § 1114.27 — Review procedure: FDA first performs an acceptance review to determine whether the PMTA may be accepted for substantive review; during the September 2020 filing cohort, FDA accepted only a fraction of the 6.5 million applications submitted for substantive review, finding millions scientifically incomplete; applications that pass acceptance review undergo substantive review, during which FDA evaluates whether the product meets the APPH standard; FDA may send a Deficiency Letter identifying missing data and allow the applicant to supplement — the deficiency/response cycle can extend review significantly
  • § 1114.31 — Issuance of a marketing granted order (MGO): FDA issues an MGO if it finds none of the grounds for denial under section 910(c)(2) of the FDCA exist; the MGO specifies the exact product authorized, including its formulation, flavoring, and labeling; any change to an authorized product requires a supplemental PMTA or a prior-approval supplement depending on the significance of the change; as of 2025, FDA has issued MGOs for a very limited set of products — primarily tobacco-flavored e-cigarettes from major manufacturers (VUSE from R.J. Reynolds, NJOY from Altria) — while denying authorization for virtually all menthol and flavored vaping products
  • § 1114.33 — Issuance of a marketing denial order (MDO): FDA issues an MDO if it determines the product is not APPH — because the risk of youth initiation or continued use outweighs the benefit to existing smokers, or because the application lacks adequate data to make the APPH finding; an MDO requires the applicant to immediately stop marketing the product; MDOs are publicly posted; applicants may seek administrative review or file for judicial review; the 2021–2023 wave of MDOs against millions of flavored e-cigarette products — many of which remained on the market in violation of the MDOs — exposed enforcement gaps that FDA has been slowly closing through warning letters, seizures, and injunctions
  • § 1114.35 — Withdrawal of a marketing granted order: FDA may withdraw an MGO if it determines the product is no longer APPH due to new data (such as evidence of youth use emerging after authorization), or if the manufacturer has changed the product from the authorized formulation without prior FDA approval; withdrawal requires notice and opportunity to respond except in emergencies
  • § 1114.39 — Postmarket changes: a marketing granted order authorizes one specific product; prior to introducing any change to an authorized product (formulation, components, labeling), the manufacturer must determine whether the change requires a new PMTA, a supplemental application, or falls within an authorized variation; FDA guidance specifies which types of changes are "major" (requiring new PMTA), "moderate" (requiring prior-approval supplement), or "minor" (permitting 30-day notification); failure to submit a required supplemental application renders the modified product an unauthorized new tobacco product subject to enforcement

  The practical consequence of Part 1114 for the e-cigarette market has been dramatic: manufacturers with pending PMTAs are in a legal limbo called "marketing authorization status" — they can continue selling while their applications are under review, but face removal if FDA ultimately denies them. As of 2026, millions of flavored vape products remain on the U.S. market without FDA authorization, either because applications were denied and the manufacturer hasn't complied with the MDO, or because the manufacturer never submitted a PMTA. Recent rulemakings: 86 FR 55300 (October 5, 2021) — Part 1114 final rule.

• 21 CFR Part 1140 — Cigarette and smokeless tobacco sale/distribution restrictions

• 21 CFR Part 1141 — Required Warnings for Cigarette Packages and Advertisements: FDA's implementation of the Federal Cigarette Labeling and Advertising Act (15 U.S.C. § 1333) as amended by the Family Smoking Prevention and Tobacco Control Act (2009), requiring graphic health warnings on all cigarette packaging and advertising. Part 1141 is the regulatory backbone of FDA's consumer-facing tobacco warning system. Key provisions:

  • § 1141.10 — Required warnings: cigarette packages and advertisements must display one of 11 textual warning statements — including "WARNING: Tobacco smoke can harm your children," "WARNING: Smoking causes fatal lung disease in nonsmokers," "WARNING: Quitting smoking now greatly reduces serious risks to your health," and others covering addiction, heart disease, impotence, pregnancy risks, and secondhand smoke; each warning must be accompanied by a color graphic image depicting the health consequence described; the FDA has specified required graphic images (lung cancer images, diseased hearts, etc.) following years of litigation over the First Amendment limits on compelled speech in warning labels
  • § 1141.12 — Misbranding: a cigarette package is deemed misbranded under the FDCA if it does not bear a required warning in accordance with the Federal Cigarette Labeling and Advertising Act; misbranded cigarettes cannot be introduced into commerce; misbranding applies to both domestic and imported cigarettes; each unit package (including cartons and single packs) must bear the required warning
  • § 1141.3 — Definitions: "cigarette" includes any roll of tobacco wrapped in paper or tobacco-containing material that is not classified as a cigar — the definition is broad enough to capture novel products marketed as cigarettes even if packaging differs; products meeting the definition cannot avoid warning requirements through rebranding

  The history of graphic warning labels under Part 1141 has been litigated extensively. The 2009 Tobacco Control Act required FDA to require color graphic warnings on at least 50% of cigarette package surfaces. FDA issued a 2012 rule with graphic images; the D.C. Circuit struck it down in R.J. Reynolds Tobacco Co. v. FDA (2012) as violating the First Amendment by compelling commercial speech without sufficient government interest evidence. FDA spent years developing a new rule backed by consumer research; the final rule requiring graphic warnings was issued in March 2020 (85 FR 15638). After multiple compliance-date delays, the Fifth Circuit upheld the rule against First Amendment challenge on March 21, 2024 (R.J. Reynolds v. FDA); FDA then announced it would begin enforcement on December 12, 2025. However, on January 14, 2025 the district court entered a preliminary injunction postponing the effective date, and on August 29, 2025 the U.S. District Court for the Southern District of Georgia vacated the final rule in Philip Morris USA v. FDA; FDA is appealing. As of May 2026 the graphic warnings are not in force. Recent rulemakings: 85 FR 15638 (March 2020) — final graphic warning rule.

Pending Legislation (119th Congress)

• S 1742 (Sen. Durbin, D-IL) — Children Don't Belong on Tobacco Farms Act. Bans under-18s from direct contact with tobacco plants or dried leaves and updates the FLSA child-labor prohibition. Status: Introduced.
• S 3148 — END Illicit Chinese Tobacco Act. Would let HHS destroy adulterated, misbranded, or counterfeit tobacco offered for import. Status: Introduced.
• HR 1798 (Rep. Krishnamoorthi, D-IL) — End Tobacco Loopholes Act. Raises and aligns tobacco taxes, taxes extracted nicotine used in vaping, creates single-use unit rules, and adds floor-stock taxes. Status: Introduced.
• HR 6844 — Tobacco TRACE Act. Would require tobacco product labeling codes by June 1, 2026 to enable tracking through the distribution system. Status: Introduced.
• HR 3335 (Rep. DeLauro, D-CT) — Children Don't Belong on Tobacco Farms Act. Would ban under-18 workers from tobacco-related agriculture. Status: Introduced.
• HR 5986 — END Illicit Chinese Tobacco Act (House companion). Would let FDA destroy counterfeit tobacco products offered for import. Status: Introduced.
• S 2064 (Sen. Blunt Rochester, D-DE) — Helping Tobacco Users Quit Act. Would require Medicaid and CHIP to cover counseling and drugs for tobacco cessation with no cost-sharing. Status: Introduced.
• S 819 (Sen. Durbin, D-IL) — End Tobacco Loopholes Act. Would align tobacco excise taxes, raise many product rates, and create a new federal tax on nicotine for vaping. Status: Introduced.
• S 4257 — A bill to apply user fees with respect to tobacco products deemed subject to chapter IX of the FD&C Act. Status: Introduced.

Recent Developments

• Trump administration and FDA tobacco rollbacks (2025): The Trump FDA under HHS Secretary RFK Jr. withdrew several Biden-era tobacco regulatory actions. The proposed menthol cigarette ban — which had been proposed in April 2022 but never finalized after the Biden administration shelved it amid political pressure in 2024 — was formally withdrawn from the rulemaking agenda in 2025. The nicotine reduction rule (which would have required cigarettes to be manufactured with minimally addictive nicotine levels) was also withdrawn as inconsistent with the administration's deregulatory posture. FDA's Center for Tobacco Products continued authorizing Premarket Tobacco Product Applications for new products but at a slower pace, reflecting both DOGE staffing reductions at FDA and the changed regulatory priorities.
• RFK Jr. and unconventional tobacco focus: Secretary Kennedy's "Make America Healthy Again" agenda at HHS produced some unusual approaches to tobacco. Kennedy expressed interest in harm reduction pathways (tobacco-free nicotine products, e-cigarettes as cessation aids) but also skepticism of pharmaceutical industry influence on FDA decision-making. FDA tobacco regulation under Kennedy's tenure was marked by policy inconsistency, with traditional tobacco deregulation (menthol ban withdrawal) occurring simultaneously with rhetoric about reducing chronic disease from tobacco.
• E-cigarettes and vaping enforcement: FDA has authorized a limited set of PMTA applications for e-cigarette products (primarily tobacco-flavored products from Vuse and NJOY/Altria) while denying millions of others. Enforcement against unauthorized flavored vape products — the primary driver of youth vaping — has been inconsistent. Youth vaping rates peaked in 2019 at ~28% of high schoolers and declined to approximately 10-12% by 2025, but new product categories (nicotine pouches, disposable vapes) continue to attract youth use. Nicotine pouches (Zyn, On!, Velo) are the fastest-growing tobacco product category and are regulated under the Tobacco Control Act as smokeless tobacco products with abbreviated PMTA requirements.
• Cigarette nicotine reduction rule status: The proposed nicotine reduction rule — which would have required cigarettes to contain no more than 0.7 mg nicotine per gram of tobacco (compared to current levels of 10-14 mg/g) — was withdrawn in 2025. This rule, if implemented, would have been the most transformative FDA tobacco regulation since the Tobacco Control Act itself. Tobacco companies had prepared for years of litigation challenging the FDA's authority. Its withdrawal under Trump removes what would have been the single most effective intervention to reduce smoking initiation among youth and prompt cessation among adult smokers.